From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases

EH Pilkington, EJA Suys, NL Trevaskis, AK Wheatley… - Acta biomaterialia, 2021 - Elsevier
Vaccination represents the best line of defense against infectious diseases and is crucial in
curtailing pandemic spread of emerging pathogens to which a population has limited …

The challenge and prospect of mRNA therapeutics landscape

Y Weng, C Li, T Yang, B Hu, M Zhang, S Guo… - Biotechnology …, 2020 - Elsevier
Messenger RNA (mRNA)-based therapeutics hold the potential to cause a major revolution
in the pharmaceutical industry because they can be used for precise and individualized …

[HTML][HTML] mRNA-based therapeutics—developing a new class of drugs

U Sahin, K Karikó, Ö Türeci - Nature reviews Drug discovery, 2014 - nature.com
In vitro transcribed (IVT) mRNA has recently come into focus as a potential new drug class to
deliver genetic information. Such synthetic mRNA can be engineered to transiently express …

Therapeutic cancer vaccines

CJM Melief, T van Hall, R Arens… - The Journal of …, 2015 - Am Soc Clin Investig
The clinical benefit of therapeutic cancer vaccines has been established. Whereas
regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in …

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose

JS Chahal, OF Khan, CL Cooper… - Proceedings of the …, 2016 - National Acad Sciences
Vaccines have had broad medical impact, but existing vaccine technologies and production
methods are limited in their ability to respond rapidly to evolving and emerging pathogens …

Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems

S Guan, J Rosenecker - Gene therapy, 2017 - nature.com
Because of its safe and effective protein expression profile, in vitro transcribed messenger
RNA (IVT-mRNA) represents a promising candidate in the development of novel …

Engineered nucleic acids encoding a modified erythropoietin and their expression

JP Schrum, NB Afeyan, GJ Sieczkiewicz… - US Patent …, 2014 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

RNA‐based vaccines in cancer immunotherapy

MA McNamara, SK Nair, EK Holl - Journal of immunology …, 2015 - Wiley Online Library
RNA vaccines traditionally consist of messenger RNA synthesized by in vitro transcription
using a bacteriophage RNA polymerase and template DNA that encodes the antigen (s) of …

Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin

K Karikó, H Muramatsu, JM Keller, D Weissman - Molecular Therapy, 2012 - cell.com
Advances in the optimization of in vitro-transcribed mRNA are bringing mRNA-mediated
therapy closer to reality. In cultured cells, we recently achieved high levels of translation with …

Terminally modified RNA

T Chakraborty, S Bancel, SG Hoge, A Roy… - US Patent …, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …